Danish children at risk from psychotropic medicines; tighter controls may needed

25 June 2010

Between 1998 and 2007, psychotropic medications were associated with 429 adverse drug reactions (ADRs) in children aged under 17 in Denmark. Researchers writing in the open access journal BMC Research Notes found that more than half of these were serious and several were birth defects - suggesting that tighter controls on the prescription of psychotropic medications to pregnant women may be required.

Lise Aagaard and Ebba Holme Hansen from the University of Copenhagen, Denmark, studied all 4,500 pediatric adverse drug reaction reports submitted during the study period to find those which were linked to psychotropic medications. Ms Aagaard said: "The high number of serious ADRs reported for psychotropic medicines in the pediatric population should be a concern for health care professionals and physicians".

The two researchers found that the largest share of adverse reactions (42%) was reported for psychostimulants (such as Ritalin; methylphenidate), followed by 31% for antidepressants (such as Prozac; fluoxetine) and 24% for antipsychotics (such as Haldol; haloperidol).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical